X
[{"orgOrder":0,"company":"Forte Biosciences","sponsor":"","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Tocagen and Forte Biosciences Announce Merger","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Forte Biosciences"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcutis Announces Enrollment of First Patient in Phase 1\/2b Study of ARQ-252 in Patients with Chronic Hand Eczema","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Arcutis Biotherapeutics"},{"orgOrder":0,"company":"Histogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Histogen Receives US FDA IND Approval to Initiate Phase 1b\/2a Trial of HST 001 in Androgenic Alopecia","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Histogen"},{"orgOrder":0,"company":"Histogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Histogen Begins Enrollment in Phase 1b\/2a Trial of HST 001 to Treat Androgenic Alopecia","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Histogen"},{"orgOrder":0,"company":"Forte Biosciences","sponsor":"Forte Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Forte Biosciences, Inc. Announces Closing of Merger With Tocagen","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Forte Biosciences"},{"orgOrder":0,"company":"Forte Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Forte Biosciences, Inc. Announces Issuance of New U.S. Patent","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Forte Biosciences"},{"orgOrder":0,"company":"Amytrx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amytrx Therapeutics Emerges from Stealth to Develop Novel Therapies for Inflammatory Diseases with Lead Program AMTX-100","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Peptide","graph2":"Amytrx Therapeutics"},{"orgOrder":0,"company":"Micreos Human Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Micreos Initiates Clinical Trial to Evaluate World\u2019s First Endolysin-Drug as a Therapy for Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Micreos Human Health"},{"orgOrder":0,"company":"Castle Creek Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Castle Creek Biosciences Announces First Patient Dosed in Phase 1\/2 Clinical Trial of FCX-013 Gene Therapy","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Castle Creek Biosciences"},{"orgOrder":0,"company":"BenevolentAI","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BenevolentAI Announces First Patient Dosed In Its Atopic Dermatitis Clinical Trial","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"BenevolentAI"},{"orgOrder":0,"company":"Kintor Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kintor Pharmaceuticals Sucessfully Dosed First Batch of Patients for Acne Vulgaris Phase I\/II Clinical Trial of Pyrilutamide","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Kintor Pharmaceutical"},{"orgOrder":0,"company":"Soligenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Soligenix to Advance Synthetic Hypericin Development in Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Soligenix"},{"orgOrder":0,"company":"Micreos Human Health","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$37.1 million","upfrontCash":"Undisclosed","newsHeadline":"Micreos Secures \u20ac32 Million for Its Endolysin-Based Platform as Sustainable Alternative to Antibiotics","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Micreos Human Health"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VYNE Therapeutics Enrolls First Patient in Clinical Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"October 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"VYNE Therapeutics"},{"orgOrder":0,"company":"Siolta Therapeutics","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"D","amount":"$1.0 million","upfrontCash":"Undisclosed","newsHeadline":"Siolta Therapeutics Awarded NIH Grant","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Siolta Therapeutics"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VYNE Therapeutics Announces Positive Phase 1b Efficacy Data for FMX114 from Phase 1b\/2a Trial for the Treatment of Mild-to-Moderate Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"VYNE Therapeutics"},{"orgOrder":0,"company":"Amytrx Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$18.0 million","upfrontCash":"Undisclosed","newsHeadline":"Amytrx Therapeutics Raises $18M For New Therapeutic Interventions of Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Peptide","graph2":"Amytrx Therapeutics"},{"orgOrder":0,"company":"BiomX","sponsor":"Maruho","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IND Accepted to Conduct Clinical Testing of BX005 for the Treatment of Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"BiomX"},{"orgOrder":0,"company":"Amytrx Therapeutics","sponsor":"Amarex Clinical Research","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amytrx Therapeutic's AMTX-100 CF3 Moves to Phase II Clinical Trial for Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Peptide","graph2":"Amytrx Therapeutics"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VYNE Therapeutics Completes Enrollment in Phase 2a Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"VYNE Therapeutics"},{"orgOrder":0,"company":"Soligenix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Soligenix Receives FDA IND Clearance for Phase 2 Clinical Trial of Synthetic Hypericin in the Treatment of Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Soligenix"},{"orgOrder":0,"company":"Siolta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Siolta Therapeutics Announces First Newborn Dosed in Their Phase 2 ADORED Study Evaluating a Potential First-In-Class Live Biotherapeutic Product for the Prevention of Atopic Diseases","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Siolta Therapeutics"},{"orgOrder":0,"company":"Amytrx Therapeutics","sponsor":"AmbioPharm","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Amytrx Therapeutics Partners With AmbioPharm to Expand the Potential of Its Breakthrough Leukocyte-Targeting Anti-Inflammatory Human Peptides","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Peptide","graph2":"Amytrx Therapeutics"},{"orgOrder":0,"company":"Dermaliq Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dermaliq Therapeutics Announces First Patient Dosed in Phase 1b\/2 Trial Evaluating DLQ02 for Treatment of Plaque Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Dermaliq Therapeutics"},{"orgOrder":0,"company":"VYNE Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VYNE Therapeutics Announces Results from its Phase 2a Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"August 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"VYNE Therapeutics"},{"orgOrder":0,"company":"Eirion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eirion Therapeutics Announces Initiation of First-in-Human Clinical Trial Evaluating Next Generation, Ready-to-Use Liquid Injectable Neuromodulator AI-09 for the Treatment of Wrinkles","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Eirion Therapeutics"},{"orgOrder":0,"company":"Micreos Human Health","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$24.5 million","upfrontCash":"Undisclosed","newsHeadline":"Micreos\u2019 Alternative to Antibiotics Secures Next \u20ac25 Million","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Micreos Human Health"},{"orgOrder":0,"company":"Dermaliq Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dermaliq Therapeutics Announces First Participant Randomized in Phase 1b\/2 Trial Evaluating DLQ01 Solution for Treatment of Androgenic Alopecia","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Dermaliq Therapeutics"}]
Find Dermatology Drugs in Phase I/II Clinical Development
Filters
×
FILTER:
Company
Sponsor
Country
Product Type
News Type
Details:
DLQ01 solution is a topical prostaglandin (PG) F2α drug, designed to stimulate scalp hair growth in men and women suffering from androgenic alopecia, also known as male and female pattern baldness.
Lead Product(s):
DLQ01
Therapeutic Area: Dermatology
Product Name: DLQ01
Highest Development Status: Phase I/ Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
December 14, 2022
Details:
Proceeds includes the clinical development of XZ.700 for endolysins against staphylococci (including MRSA) for Bloodstream Infections, Atopic Dermatitis, Diabetic Foot Ulcers and Cutaneous T-cell Lymphoma, a type of skin cancer associated with presence of S. aureus bacteria.
Lead Product(s):
XZ.700
Therapeutic Area: Dermatology
Product Name: XZ.700
Highest Development Status: Phase I/ Phase II
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Undisclosed
Deal Size: $24.5 million
Upfront Cash: Undisclosed
Deal Type: Financing
October 25, 2022
Details:
AI-09 (botulinum toxin) employs a proprietary technology that allows an injectable botulinum to be formulated as a convenient, ready-to-use liquid product, instead of requiring reconstitution with saline prior to use.
Lead Product(s):
Botulinum Toxin
Therapeutic Area: Dermatology
Product Name: AI-09
Highest Development Status: Phase I/ Phase II
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
October 17, 2022
Details:
DLQ02 is a liquid topical, calcineurin inhibitor with anti-inflammatory and immunomodulating properties, developed for the treatment of skin disease psoriasis.
Lead Product(s):
DLQ02
Therapeutic Area: Dermatology
Product Name: DLQ02
Highest Development Status: Phase I/ Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
August 18, 2022
Details:
Mean reduction in ADSI score from baseline was -4.05 (-60.62% mean reduction) for FMX114 (tofacitinib) treated lesions compared to -3.48 (-51.32% mean reduction) for vehicle treated lesions at week 4 (p=0.228, OC, ITT).
Lead Product(s):
Tofacitinib Citrate ,Fingolimod Hydrochloride
Therapeutic Area: Dermatology
Product Name: FMX114
Highest Development Status: Phase I/ Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
August 10, 2022
Details:
Amytrx has identified new opportunities for other inflammatory and metabolic diseases with attractive out-licensing and collaborative opportunities using its proprietary AMTX-100 human peptide platform.
Lead Product(s):
AMTX-100
Therapeutic Area: Dermatology
Product Name: AMTX-100
Highest Development Status: Phase I/ Phase II
Product Type: Peptide
Partner/Sponsor/Collaborator:
AmbioPharm
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Partnership
July 26, 2022
Details:
STMC-103H is a Live Biotherapeutic Product (LBP) for the prevention and treatment of atopic diseases (atopic dermatitis, atopic asthma, food allergy, allergic rhinitis) in at-risk newborns based on an immediate family history of atopic diseases.
Lead Product(s):
STMC-103H
Therapeutic Area: Dermatology
Product Name: STMC-103H
Highest Development Status: Phase I/ Phase II
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
July 20, 2022
Details:
Visible light-activated synthetic hypericin (SGX302) is a novel, first-in-class, photodynamic therapy (PDT), a photosensitizer that is topically applied to skin lesions and taken up by cutaneous T-cells.
Lead Product(s):
Hypericin
Therapeutic Area: Dermatology
Product Name: SGX302
Highest Development Status: Phase I/ Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
June 28, 2022
Details:
FMX114 (tofacitinib), is VYNE’s proprietary investigational combination gel formulation of tofacitinib and fingolimod, which has been designed to address both the source and cause of inflammation in AD.
Lead Product(s):
Tofacitinib Citrate ,Fingolimod Hydrochloride
Therapeutic Area: Dermatology
Product Name: FMX114
Highest Development Status: Phase I/ Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
June 17, 2022
Details:
AMTX-100 CF3, its leading drug candidate, is known for its ability to transport across membranes, address inflammation and modulate immune mediated diseases instead of simply inhibiting inflammation.
Lead Product(s):
AMTX-100
Therapeutic Area: Dermatology
Product Name: AMTX-100
Highest Development Status: Phase I/ Phase II
Product Type: Peptide
Partner/Sponsor/Collaborator:
Amarex Clinical Research
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
June 09, 2022